share_log

Stocks of the Hour: Tamboran Res, Sayona Mining, BCAL Diagnostics, Nova Eye Medical

Stocks of the Hour: Tamboran Res, Sayona Mining, BCAL Diagnostics, Nova Eye Medical

熱門股票:Tamboran Res、Sayona Mining、BCAL 診斷、Nova Eye Medical
sharecafe ·  2023/08/02 09:50

Tamboran Resources (ASX:TBN) has signed four separate non-binding Letters of Intent with Origin, AGL, EnergyAustralia and Shell Energy Australia to potentially purchase gas from Tamboran's low-reservoir Beetaloo Basin gas assets for a period of up to 10 – 15 years. In response, Managing Director and CEO, Joel Riddle, said: "The initial interest from key East Coast gas buyers for the long-term purchase of Tamboran's low-reservoir CO2 Beetaloo Basin gas volumes demonstrates gas' viability and role in the energy transition in Australia." Shares are trading 3.33 per cent higher at 15.5 cents.

Tamboran Resources (ASX: TBN) 已分別與Origin、AGL、EnergyAustralia和澳大利亞殼牌能源公司簽署了四份不具約束力的意向書,有可能在長達10至15年的時間內從坦博蘭的低儲量Beetaloo盆地天然氣資產中購買天然氣。作爲回應,董事經理兼首席執行官喬爾·裏德爾表示:“東海岸主要天然氣買家最初對長期購買坦博蘭低儲層二氧化碳Beetaloo盆地天然氣量的興趣表明了天然氣的可行性和在澳大利亞能源轉型中的作用。”股價上漲3.33%,至15.5美分。

Sayona Mining (ASX:SYA; OTCQB:SYAXF) announced the first commercial shipment of spodumene concentrate from the North American Lithium operation in Québec, Canada. In response, Sayona's Managing Director, Brett Lynch commented: "We are particularly pleased to make this first shipment in less than two years since NAL's acquisition in August 2021, reflecting the team's strong execution capabilities and commitment." Shares are trading 3.23 per cent higher at 16 cents.

Sayona Mining (ASX: SYA; OTCQB: SYAXF) 宣佈,加拿大魁北克的北美鋰業務首次商業運送鋰輝石精礦。作爲回應,Sayona董事經理Brett Lynch評論說:“我們特別高興能夠完成自2021年8月NAL被收購以來不到兩年來的第一批貨物,這反映了該團隊強大的執行能力和承諾。”股價上漲3.23%,至16美分。

BCAL Diagnostics (ASX:BDX) has received breakthrough results from their Precion US study. The Precion result enables blood samples to be analysed in many commercial laboratories worldwide fast tracking market access and penetration. In response, Jayne Shaw, Executive Chair of BCAL commented "We will continue to work closely with leading scientists and doctors as our science team further optimises the test to make it more cost-effective when it is launched as a patient friendly blood test for detecting breast cancer". Shares are trading 81.25 per cent higher at 14.5 cents.

BCAL Diagnostics (ASX: BDX) 的美國Precion研究取得了突破性的結果。Precion的結果使全球許多商業實驗室能夠對血液樣本進行分析,從而快速追蹤市場準入和滲透率。作爲回應,BCAL執行主席Jayne Shaw評論說:“我們將繼續與領先的科學家和醫生密切合作,因爲我們的科學團隊進一步優化該測試,使其在作爲檢測乳腺癌的患者友好型血液測試推出時更具成本效益”。股價上漲81.25%,至14.5美分。

Nova Eye Medical (ASX:EYE) announced that following the US launch of iTrack, total USA sales in the three months to 31 July 2023 were approx. US$2.2 million, up 32% on the prior corresponding period. In response, Managing Director, Tom Spurling, commented: "We will continue to reactivate inactive customer accounts before turning our focus to win new customer accounts in the remainder of the calendar year." Shares are trading 12 per cent higher at 28 cents.

Nova Eye Medical (ASX: EYE) 宣佈,在美國推出iTrack之後,截至2023年7月31日的三個月中,美國的總銷售額約爲220萬美元,比上一同期增長32%。作爲回應,董事經理湯姆·斯普林評論說:“在本日曆年的剩餘時間裏,我們將繼續重新激活不活躍的客戶賬戶,然後將注意力轉向贏得新的客戶賬戶。”股價上漲12%,至28美分。

1x1.png?futu_img_keep_extra_domain=1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論